BSX Quote, Financials, Valuation and Earnings

Baxter International has a net margin of 11.12% compared to Boston Scientific's net margin of 5.19%. Boston Scientific's return on equity of 8.91% beat Baxter International's return on equity of 1.33%.

Boston Scientific has a consensus price target of $99.14, signalling upside risk potential of 10.33%. On the other hand Baxter International has an analysts' consensus of -- which suggests that it could grow by 39.45%. Given that Baxter International has higher upside potential than Boston Scientific, analysts believe Baxter International is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.802, which suggesting that the stock is 19.799% less volatile than S&P 500. In comparison Baxter International has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.462%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 3.56% to investors and pays a quarterly dividend of $0.17 per share. Boston Scientific pays 1.76% of its earnings as a dividend. Baxter International pays out 22.06% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.2B, which are larger than Baxter International quarterly revenues of $2.7B. Boston Scientific's net income of $468M is higher than Baxter International's net income of $140M. Notably, Boston Scientific's price-to-earnings ratio is 74.26x while Baxter International's PE ratio is 145.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.37x versus 0.86x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 11.12% compared to Boston Scientific's net margin of 8.28%. Boston Scientific's return on equity of 8.91% beat Globus Medical's return on equity of 2.27%.

Boston Scientific has a consensus price target of $99.14, signalling upside risk potential of 10.33%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 13.39%. Given that Globus Medical has higher upside potential than Boston Scientific, analysts believe Globus Medical is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.802, which suggesting that the stock is 19.799% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays 1.76% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.2B, which are larger than Globus Medical quarterly revenues of $625.7M. Boston Scientific's net income of $468M is higher than Globus Medical's net income of $51.8M. Notably, Boston Scientific's price-to-earnings ratio is 74.26x while Globus Medical's PE ratio is 124.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.37x versus 4.60x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of 11.12% compared to Boston Scientific's net margin of 9.79%. Boston Scientific's return on equity of 8.91% beat Haemonetics's return on equity of 13.51%.

Boston Scientific has a consensus price target of $99.14, signalling upside risk potential of 10.33%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 43.56%. Given that Haemonetics has higher upside potential than Boston Scientific, analysts believe Haemonetics is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.802, which suggesting that the stock is 19.799% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays 1.76% of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.2B, which are larger than Haemonetics quarterly revenues of $345.5M. Boston Scientific's net income of $468M is higher than Haemonetics's net income of $33.8M. Notably, Boston Scientific's price-to-earnings ratio is 74.26x while Haemonetics's PE ratio is 32.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.37x versus 2.92x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 11.12% compared to Boston Scientific's net margin of 25.43%. Boston Scientific's return on equity of 8.91% beat ResMed's return on equity of 23.76%.

Boston Scientific has a consensus price target of $99.14, signalling upside risk potential of 10.33%. On the other hand ResMed has an analysts' consensus of $206.05 which suggests that it could grow by 9.49%. Given that Boston Scientific has higher upside potential than ResMed, analysts believe Boston Scientific is more attractive than ResMed.

Boston Scientific has a beta of 0.802, which suggesting that the stock is 19.799% less volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Boston Scientific pays 1.76% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.2B, which are larger than ResMed quarterly revenues of $1.2B. Boston Scientific's net income of $468M is higher than ResMed's net income of $311.4M. Notably, Boston Scientific's price-to-earnings ratio is 74.26x while ResMed's PE ratio is 30.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.37x versus 7.09x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.